Antimalarial Drugs
Substantial increase in malaria-infected persons across the globe is positively influencing the market growth of antimalarial drugs. According to the World Health Organization (WHO), an estimated 3.4 billion people in 92 countries are at risk of being infected with malaria and developing a disease, and 1.1 billion are at high risk in 2018. According to the World Malaria Report 2018, there were 219 million cases of malaria globally in 2017 (uncertainty range 203–262 million) and 435,000 mortalities from malaria, representing a decrease in malaria cases and deaths rates of 18% and 28% since 2010, respectively. The burden was heaviest in Africa, where an estimated 93% of all malaria fatalities occurred, and in children aged under 5 years, who accounted for 61% of all mortalities. The increasing prevalence of malaria reflects the demand for various antimalarial drugs for its treatment; thereby, expanding its global market size.
Recent COVID-9 outbreak has further escalated the demand for some antimalarial drugs
According to the Worldometers, global coronavirus cases reached over 1.4 million with death toll around 83,000 as of 8th April 2020. With nearly 400,500 infected persons, the US is majorly affected due to the virus spread. The US followed by Spain and Italy with cases around 146,690 and 135,586 respectively as of 8th April 2020. With no vaccine in place, the governments of several nations have taken precautionary measures to lower the spread of the virus. The spread of the deadliest virus has forced the government of several nations to lock down streets, cities, and states of the country. Cinema halls, restaurants, cafeterias, pubs, bars, and other entertainment places have been shut down to keep people away from social distancing.
However, as some countries including global superpowers completely ignored the advent of COVID-19 spread at the first stage and ultimately entered into the community transmission stage, the situation has gone out of control. However, with no approved vaccine in the market place as of now, there have been some antiviral drugs that are quite effective to reduce the viral shedding in the respiratory secretions of patients with COVID-19. Hydroxychloroquine, an antimalarial drug, is licensed for the chemoprophylaxis and treatment of malaria as well as a disease-modifying antirheumatic drug. Moreover, the drug has a history of being safe and well-tolerated at typical doses. Notably, the drug shows antiviral activity in vitro against coronaviruses, and specifically, SARS-CoV-2. Owing to the drug effectiveness, various virus affected nations have begun using hydroxychloroquine drugs on the affected patients and have turned up towards India for the bulk supply of the drug.
Although the coronavirus cases in India are quite low as compared to other economies, the nation has ensured the stock of essential drugs such as hydroxychloroquine which can be further used on local patients if the spread accelerates in the near future. Following this, the Indian government has banned the export of such drugs on 26th March 2020. However, after the US President Donald Trump’s appeal, India allowed supplies of the drugs. On 8th April 2020, the US announced that it has bought over 29 million hydroxychloroquine doses from India. Moreover, Brazil with around 14,000 cases and 688 death tolls has also sought the supply of hydroxychloroquine doses from India. As per the Indian Brand Equity Fund (IBEF), India enjoys an important position in the global pharmaceutical sector and the country is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50% of global demand for various vaccines, 40% of generic demand in the US, and 25% of all medicine in UK. Presently more than 80% of the antiretroviral drugs used globally to combat AIDS are supplied by Indian pharmaceutical firms.
OMR Global Recently Published Report on:https://www.omrglobal.com/industry-reports/antimalarial-drugs-market
The Report Covers
- Comprehensive research methodology of the Global Antimalarial Drugs Market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Global Antimalarial Drugs Market.
- Insights about market determinants that are stimulating the Global Antimalarial Drugs Market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Market Segmentation
Drug Class
- Quinine
- Chloroquine
- Proguanil
- Mefloquine
- Others (Pyrimethamine)
- Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- E-Commerce
To Learn More About this Report Request a Free Sample Copy @ https://www.omrglobal.com/request-sample/antimalarial-drugs-market
